RecruitingNot Applicable

Role of Endothelial Progenitor Cells Dysregulation and Inflammation in the Pathophysiology of Cardiovascular Complications of Type 2 Diabetes

Qatar90 participantsStarted 2020-11-17

Plain-language summary

This study aims to isolate endothelial progenitor cells (EPCs) from participants with type 2 diabetes (T2D) and cardiovascular complications and to comprehensively characterize EPC dysfunction. Specifically, the study will evaluate maladaptive angiocrine signaling, calcium signaling pathways, and the role of inflammation in EPC function and the progression of atherosclerosis during T2D development. A sub-study will assess EPC functionality by examining endothelial nitric oxide synthase (eNOS) expression and activity, as well as the effectiveness of in vitro eNOS gene enhancement.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * T2D * Males and females * Older than 18 years of age * Willingness to participate in the study and provide written consent form * Consent to having peripheral blood withdrawals and urine collection for the study requirement. Exclusion Criteria: * Unable to meet the inclusion criteria * Type I diabetes, MODY diabetes or other form of diabetes * Active infection, inflammation, cancer or acute illness of any kind (other than a cardiovascular complication of diabetes if applicable in the group they are assigned to). * Chronic inflammation (eg. auto-immune diseases) or infections (eg. HIV, chronic hepatitis). * Evidence of malignancy within the past 5 years

What they're measuring

Characterization of EPCs dysregulation in Type 2 diabetes

Timeframe: Following the EPC isolation (15 - 20 days).

Functional Analysis of inflammatory responses in Endothelial Progenitor Cells in type 2 Diabetes with cardiovascular complications

Timeframe: Following the EPC isolation (15 - 20 days)

Trial details

NCT IDNCT07556497

SponsorWeill Cornell Medical College in Qatar

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-12-31